<< Back
November 22, 2017

ImmuncoCellular Therapeutics to Present at the 10th Annual LD Micro Main Event on December 7, 2017

LOS ANGELES, Nov. 22, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on Stem-to-T-Cell research, announced today that Anthony Gringeri, Ph.D., President and Chief Executive Officer, Steven Swanson, Ph.D., Senior Vice President, Research, and David Fractor, Chief Financial Officer, will present at the 10th Annual LD Micro Main Event on Thursday, December 7, 2017 at 9:30 a.m. PT (12:30 p.m. ET) in Track 3. The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

ImmunoCellular Therapeutics Logo. (PRNewsFoto/ImmunoCellular Therapeutics) (PRNewsFoto/IMMUNOCELLULAR THERAPEUTICS)

Management will be available for one-on-one meetings on Thursday, December 7, 2017. Investors interested in arranging a meeting with management should contact their LD Micro representative or Lytham Partners at (602) 889-9700 or

Interested parties who wish to listen to the webcast of the ImmunoCellular LD Micro presentation should visit the Investor Relations section of ImmunoCellular's website at, under the Events and Presentations tab. A replay of the webcast will be available one hour after the conclusion of the event. The webcast will contain forward-looking statements. The information provided on the webcast is accurate only at the time of the webcast, and ImmunoCellular will take no responsibility for providing updated information except as required by law.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd., based in Los Angeles, is developing immune-based therapies for the treatment of cancer. ImmunoCellular is focused on advancing its Stem-to-T-Cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells. Additional assets, for which the Company is seeking partners, include clinical-stage programs - ICT-107, ICT-121 and ICT-140 - which are patient-specific, dendritic cell-based immunotherapies targeting solid tumors. To learn more about ImmunoCellular, please visit

ImmunoCellular Therapeutics, Ltd. Contact:

Jane Green
(267) 457-3734 direct
(415) 652-4819 mobile

Investor Relations Contact:

Lytham Partners, LLC 
Joe Dorame, Robert Blum, or Joseph Diaz
(602) 889-9700


View original content with multimedia:

SOURCE ImmunoCellular Therapeutics, Ltd.

News Provided by Acquire Media

Copyright 2018 by Immunocellular Therapeutics, Ltd.
All Rights Reserved